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Abstract
Introduction—Elevated rate of aging-related biological and functional decline, termed
accelerated aging, is reported in patients with schizophrenia (SCZ) and major depressive disorder
(MDD). We used diffusion tensor imaging (DTI) derived fractional anisotropy (FA) as biomarkers
of aging-related decline in white matter (WM) integrity to test the hypotheses of accelerated aging
in SCZ and MDD.
Methods—The SCZ cohort was composed of 58/60 SCZ patients/controls (age=20–60years).
MDD cohort was composed of 136/351 MDD patients/controls (age=20–79years). Main outcome
measures were the diagnosis-by-age interaction on whole-brain-averaged WM FA values and FA
values from twelve major WM tracts.
Results—Diagnosis-by-age interaction for the whole-brain average FA was significant for the
SCZ (p=0.04) but not in MDD cohort (p=0.80). Diagnosis-by-age interaction was nominally
significant (p<0.05) for five WM tracts for SCZ and for none of the tracts in the MDD cohort.
Tract-specific heterochronicity of the onset of age-related decline in SCZ demonstrated strong
negative correlations with the age-of- peak myelination and the rates of age-related decline
obtained from normative sample (r=−0.61 and −0.80, p<0.05, respectively). No such trends
existed for MDD cohort.
Conclusion—Cerebral WM showed accelerated aging in SCZ but not in MDD, suggesting some
difference in the pathophysiology underlying their WM aging changes. Tract-specific
© 2012 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
*Corresponding Author: Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of
Medicine, Baltimore, MD, USA, Phone: (410) 402-6110, Fax (410) 502-6778, pkochunov@mprc.umaryland.edu.
Financial Disclosure
The authors report no biomedical financial intersts or potential conflicts of interest.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Biol Psychiatry. Author manuscript; available in PMC 2014 March 01.
Published in final edited form as:













heterochronicity of WM development modulated presentation of accelerated aging in SCZ: white
matter tracts that matured later in life appeared more sensitive to the pathophysiology of SCZ and
demonstrated more susceptibility to disorder-related accelerated decline in FA values with age.
This trend was not observed in MDD cohort.
Introduction
Elevated rate of aging-related clinical, biological and functional decline, termed accelerated
aging(1–3), is observed in many clinical diagnoses ranging from progeria and other rare
genetic accelerated aging syndromes(3) to more common conditions such as chronic
obstructive pulmonary disease(4). Psychiatric disorders such as schizophrenia (SCZ) (1, 4,
5) and major depressive disorder (MDD)(2, 6, 7) have been postulated to increase individual
risks for accelerated aging. Specifically, schizophrenia is associated with increased rate of
cardiovascular illnesses and other conditions commonly associated with aging(8).
Schizophrenia patients have increased mortality rate and shorter (by as much as twenty
years) average lifespan even after accounting for suicide (1, 9–11). Similar findings are
emerging in MDD(2). Additionally, patients with these mental disorders are reported to have
shortened telomeres, a biomarker potentially associated with accelerated aging(6, 12).
This initial evidence for accelerated aging in SCZ and MDD raises an intriguing question on
whether the biological processes that lead to accelerated aging are the same in these two
diagnostically separated illnesses. This question is best approached using a brain measure(s)
that is sensitive for both disorders and simultaneously is a sensitive biomarker for cerebral
aging. One such a measure is the fractional anisotropy (FA) of water diffusion which reflects
the integrity of the cerebral white matter (WM)(13–16). The FA values are sensitive to age-
related alterations in cerebral WM(13, 17, 18) and are used as the endophenotypes, sensitive
to the pathophysiology of SCZ and MDD disorders(19–21). We hypothesized a diagnosis-
by-age interaction in the cerebral WM FA values in patients versus normal controls. We
tested this hypothesis in two well-characterized populations: a cohort of SCZ patients with
matched controls and a cohort of MDD patients compared with non-depression controls
(22).
Schizophrenia and depression are both associated with DTI-FA and cerebreal connectivity
deficits(23, 24). Reduced FA values are consistently reported in chronic SCZ patients(20,
25). Studies on correlations of FA vand age in SCZ have yielded contradictory results. Jones
and colleagues showed a positive correlation (26) of FA with age, while others showed a
negative correlation (19, 20). This difference could potentially be explained by the younger
age-range in Jones et al that corresponded to the portion of FA developmental trajectory
with age that peaks in the 3rd-to-4th decade of life (17, 18, 27).
Deficits in WM integrity in MDD are more regionally specific and found in the genu of
corpus callosum (GCC), cingulum and thalamic radiation(28–32). These regional FA
measurements are associated with genetic risks for MDD (21), particularly the rsik in
developing MDD in later life(21). No study, we are aware of, have examined the accelerated
age effect on FA in MDD, or compared such effects between two major psychiatric
illnesses.
We hypothesized that DTI-FA can serve as a biomarker to test accelerated aging in SCZ and
perhaps MDD. Additionally, WM tracts that carry higher level cognitive functions follow a
more protracted developmental trajectory than sensory and motor tracts and, therefore may
be more vulnerable to the neurodegenerative effects of illnesses(33, 34). Therefore, our
second hypothesis was that the WM tracts that reach peak development later in life may be
more susceptible to the effects of accelerated aging. Specifically, we evaluated if the
normative age of peak for FA values and rates of development and senescence for individual
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WM tracts that were previously calculated from large groups of normally aging individuals
(age ranged from 11–90)(27), could explain the tract-wise differences in aging trends among
SCZ, MDD, and control subjects.
Methods
Testing of the study’s hypotheses were performed in two distinct cohorts, each with own
normal control group.
SCZ cohort
Subjects—A total of 118 (19 females, average age=37.7±12.0 years, range=20–60)
individuals participated in the study at the Maryland Psychiatric Research Center (Table 1).
Among them 58 (7 females, age=37.1±12.4 years) were diagnosed with schizophrenia and
60 (12 females, age 37.5±11.9 years) were age- and gender- frequency matched healthy
controls (Table 1). Controls were recruited through media advertisements. Additional
clinical and epidemiological information is provided in Table 1. There was no significant
difference in the body mass index between SCZ patients and controls (BMI=26.9±5.6 vs.
27.0±6.0, p=0.90, respectively). The exclusion criteria included diagnosis with hypertension,
hyperlipedimia, type 2 diabetes, heart disorders, and major neurological event such as stroke
or transient ischemic attack.
Clinical Assessment—Patients were those with current Axis I schizophrenia diagnosis.
Controls were subjects without Axis I psychiatric diagnosis. Controls and patients could not
have current or past Axis I mood disorder diagnoses. Illicit substance and alcohol abuse and
dependence were exclusion criteria, enforced using breathalyzer and toxicology screen prior
to each imaging session. Except two medication-free participants, schizophrenia patients
were on antipsychotic medications: 3 were on first-generation antipsychotics and the rest
were on either secondary-generation or combined first- and second-generation
antipsychotics.
Diffusion Tensor MR imaging—Imaging data was collected using a Siemens 3T Allegra
MRI (Erlangen, Germany) located at the National Institute on Drug Abuse using a
quadrature RF head coil. DTI data was collected using a spin-echo, EPI sequence with a
spatial resolution of 1.7×1.7×4.0 mm. The sequence parameters were: TE/TR=87/5000ms,
FOV=200mm, axial slice orientation with 35 slices and no gaps, twelve isotropically
distributed diffusion weighted directions, two diffusion weighting values (b=0 and 1000 s/
mm2). Subjects’ head movement was minimized by the use of padding, hardened
polyurethane foam, and/or bite bar.
MDD cohort
Subjects—A total of 483 (311 females, age=41.6±13.6 years, range=20–79) Mexican-
American individuals, from 71 families, who participated in the Genetics of Brain Structure
and Function (GOBS) study. Among them 132 (96 females, age=42.3±12.1 years) were
diagnosed with MDD (Table 1). This cohort was further subdivided into 68 (54 females,
age=42.8±11.9 years) subjects who experienced a single major depressive episode and 64
(41 females, age=41.1±12.0 years) who experienced two or more, recurrent depressive
episodes. The remaining 351 (215 females, age 41.5±13.9 years) were without Axis I
diagnosis and were treated as controls. Additional epidemiological information is provided
in Table 1. Patients with MDD, as expected, scored higher on the Beck’s Depression
Inventory (BDI) compared with the controls (11.3±9.0 vs. 5.6±5.6, p=10−9). There was no
significant difference in the body mass index between MDD patients and controls
(BMI=31.5±6.8 vs. 30.5±6.5, p=0.14, respectively) (Table 1). Alcohol and illicit drug abuse
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and dependence were exclusionary. Schizophrenia and Axis I psychiatric disorder other than
MDD were excluded.
Clinical Assessment—All GOBS subjects received face-to-face medical and psychiatric
interviews in the subject’s language of choice (English or Spanish)(35). The Mini-
International Neuropsychiatric Interview (MINI-Plus)(36) is a semi-structured interview to
make diagnoses for DSM-IV psychiatric illnesses. Subjects with possible psychopathology
were discussed in case conferences and diagnoses were reached by consensus. MDD was
defined with DSM-IV criteria as having single versus two or more distinct episodes of
depression lasting two or more weeks.
Diffusion Tensor MR imaging—Imaging data were collected using a Siemens 3T Trio
scanner located at the Research Imaging Institute, UTHSCSA. The details of imaging
protocol are described elsewhere(18). In short, diffusion tensor data were collected using a
single-shot, echo-planar, single refocusing spin-echo, T2-weighted sequence with a spatial
resolution of 1.7×1.7×3.0 mm. The sequence parameters were:TE/TR=87/8000ms,
FOV=200mm, axial slice orientation with 50 slices and no gaps, 55 isotropically distributed
diffusion weighted directions, two diffusion weighting values (b=0 and 700 s/mm2). These
parameters were calculated using an optimization technique that maximizes the contrast to
noise ratio for FA measurements(37).
Image processing: DTI data for both cohorts was processed using a tract-based spatial
statistics (TBSS) method, distributed as a part of FMRIB Software Library (FSL) package
(38) as described elsewhere(18). The population-based, 3D, DTI cerebral WM tract atlas
developed in John Hopkins University and distributed with the FSL package(39) was used to
calculate population average FA values along the spatial course of twelve, major WM tracts
(Table 2, Figure 1) as described elsewhere(27, 40).
Statistical analysis
We employed a statistical approach previously used (17, 18) to study diagnosis-by-age
interaction on the age related FA trends. Given the known nonlinear trajectory of white
matter development, quadratic effect was a prori test although linear effect was also
reported. The model also included fixed effects of diagnosis, age and gender. The SCZ
cohort was a case-control sample composed of independent subjects from independent
families. Subjects from the MDD cohort were recruited from large families and ancestry was
included as a part of the modeling process. The effects of the familial aggregation in MDD
cohort were modeled by partitioning the intersubject variance into fixed (age, disorder, sex
and their interactions) and mixed, within-family, effects using general linear mixed effect
model. Modeling familial aggregations using the mixed model allows the results of the
analyses to be more representative for a sample of independent subjects.
Estimation of effects of age-by-diagnosis interaction—FA values were modeled as
both linear and quadratic function of age, gender and diagnosis using GLME model
presented in equation 1 and 2, respectively.
(1)
(2)
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Where FAi,j is the FA for the “jth” subject from the “ith” family, dxi,j is the diagnosis
[0=normal control, 1= disorder (SCZ or MDD)], A is the constant FA term, β is the
covariate regression coefficient and αi,j is a coefficient that accounts for random effects.
This modeling was performed with the [R] package(41) using the linear mixed effects model
library and the maximum likelihood estimation algorithm (42). Finally, the difference of
aging effects between single vs. recurrent episode MDD were compared by coding 0 for
single and 1 for recurrent in dxi,j in equations 1 and 2.
The age-by-diagnosis interactions were quantified for whole-brain average FA values in our
primary hypothesis testing.
In order to examine heterochronicity effects (see below), we first performed exploratory
tests for regional, tract-wise FA measurements and the threshold for statistical significance
of the diagnosis, age and gender model was chosen at p≤0.004, to correct for multiple
(n=12) comparisons. Nominally significant findings (p≤0.05) were deemed as potentially
interesting. The significance of the individual beta coefficients was based on p≤0.05.
Effects of anatomic heterochronicity of WM development—Different WM tracts
reach maturation peak at different age. This is termed heterochronicity of the WM
development(18, 33). We used tract-wise differences in normal cerebral development and
senescence, taken from a previous study(18), to elucidate inter-tract differences in aging
trends between patients and controls. First, a polynomial model described in Eq. 2 was used
to remove the effects of normal aging on the whole-brain and regional FA values. The
residual values were Z-normalized, by dividing them by the standard deviation calculated
from the respective control group for each cohort. To visualize the remaining difference in
aging trajectory between patients and controls, we fitted a linear age trend using a least
squares line fitting. By design, the normal controls have a zero-slope line and a negative
slope for patients would indicate accelerated aging. The intercept of the 2 slopes represents
the age-of-onset where aging related decline begins to accelerate in the patients compared
with the controls. This X-intercept value is thus the tract-specific age of onset of the
accelerated FA decline associated with the disease. We calculated the X-intercept for each
of the 12 tracts. We then obtained known tract-specific age of peak of FA value from a
normative dataset(27), representing the age each tract reaches the peak of its maturation
before FA declines with senescence. By correlating the X-intercept and the normative age of
peak FA across tracts, we test our second hypothesis that disorder-related accelerated aging
maybe sensitive to the chronological variations in maturation stages in different fiber tracts.
Results
Diagnosis and diagnosis-by-age effects for whole-brain FA values
SCZ cohort—Beta coefficients and their significance for age and gender effects for the
whole-brain average FA values are shown in Table 3. The quadratic and linear age models
were significant for the whole-brain FA values (p=6.9 × 10−5 and 9.2 × 10−5, respectively).
There were no significant main effects on diagnosis. Instead, quadratic effects of the
diagnosis-by-age interaction were significant (βage2*scz = −6.9±3.4· 10−6;p=0.04) and linear
effects of the diagnosis-by-age interaction approached significance (βage*scz =
−4.9±2.6·10−4; p=0.06).
MDD cohort—The quadratic and linear age models were significant for whole-brain
average FA but there were no significant effects of the diagnosis. Neither quadratic or linear
effects of the diagnosis-by-age interaction was significant for the MDD cohort (βage2*MDD =
−0.2±0.2·10−6, p=0.9; and βage*MDD =−0.6±1.9·10−4, p=0.7, respectively) (Figure 2). There
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were no significant differences in either linear or quadratic diagnosis-by-age interaction
between single vs. recurrent episode MDD (Table 4).
Diagnosis and diagnosis-by-age effects for regional FA values
SCZ cohort—Nominally significant effects of diagnosis were observed for SLF and SFO
WM tracts (p=0.04 and 0.03, respectively) (Supplemental Table S1). Quadratic diagnosis-
by-age interaction was nominally significant (p<0.05) for five WM tracts, including all three
partitions of CC (genu, body, and splenium) and the SLF and SFO tracts. The sign and the
magnitude of the diagnosis-by-age coefficients indicated that rate of age-related decline in
patients was more than twice the aging rate in the controls (Supplemental Table S1).
Nominally significant, linear diagnosis-by-age interaction was also observed for the genu of
CC, SLF and SFO tracts (p=0.04, 0.04 and 0.02, respectively).
MDD cohort—The quadratic diagnosis-by-age interaction was not significant for either
whole-brain average FA value or any of the tract-wise measurements. The quadratic decline
in average FA in MDD patients was slightly (by 4%) accelerated compared to the normal
controls (Supplemental Table S3). Effects of linear diagnosis-by-age interaction were not
significant for any of the twelve tracts (Supplemental Table S3).
Testing the effects of age-of-onset and the duration of the illness (Table 1) independent of
subject’s age, we found that they were no significant correlation between whole-brain FA
value in either cohort (all r<0.12, all p>0.2).
Heterochronicity of WM development on disorder-related differences in aging
SCZ cohort—Patients with schizophrenia demonstrated numerically higher age-related
decline in FA in all twelve tracts. The age-of-intercept for the average FA was 32.4 years
(SE =11.9 years) (Figure 2). Regionally, the age-of-intercept varied from 27.7 years
(SE=11.0) for the GCC to 49.9 years (SE=16.4) for the thalamic radiation (TR)
(Supplemental Figure S1). The age-of -intercept was significantly and negatively correlated
with the normative age of FA peak (r=−0.61, p=0.04) obtained from a large, independent
cohort of normal subjects(18) (Figure 4, top). This means that tracts that are normally
matured slowly and reach FA peak late are vulnerable to earlier onset of accelerated aging in
FA in SCZ. We also obtained the normative rate of age-related decline in FA(18) and found
that it is was negatively and robustly correlated with the age of X-intercept (Pearson’s r=
−0.80, p=0.005; Figure 4, bottom). This means that tracts that are normally associated with
steeper age-related decline in FA also have earlier onset of accelerated aging in FA in SCZ.
Thus, heterochronicity of the tract-specific age-related maturation and decline explained
37% and 64%, respectively, of the variance on onset of accelerated aging in SCZ.
MDD cohort—Patients with MDD demonstrated numerically higher age-related decline in
FA for seven tracts, when compared to normal controls (none were statistically significant:
genu of CC, body of CC, internal capsule, external capsule, Cingulum, SLF and inferior
frontal occipital) (Supplemental Figure S2). The age of intercept varied from −251.5 years
(standard error (SE) =72.0 years) for the Sagittal Striatum to 82.1 years (SE=21.7) for the
IC. These values suggest that there is no evidence of tract-specific accelerated aging
occurring during the normal life span in MDD. The age-of-intercept in the MDD group was
not significantly correlated with the normative age of FA peak or decline across tracts
(−0.04, and −0.21, respectively; p>.20).
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We aimed to test if the rates of age-related decline in the integrity of cerebral WM were
higher in patients affected with SCZ or MDD than in normal controls. In SCZ patients, age-
related decline in the whole-brain FA values were more than twice that of controls,
significant under the quadratic model. In contrast, the effects of accelerated aging in the
whole-brain FA values were not statistically significant in the MDD patients. Exploration of
regional differences provided a more wide-spread evidence for accelerated aging in SCZ
patients, with nominally significant effects of accelerated aging observed in five, associative
WM tracts, but none in MDD. (The closest track that approached statistical significance was
genu of CC, p=0.09, not significant, in MDD). Therefore, we observed an intriguing disease-
specific pattern of the accelerated aging in the WM integrity that is specifically present in
the SCZ patients while evidence of the same effect was much weaker in MDD, suggesting
some differences in the biological processes underlying the FA changes in these two
disorders.
This observation prompted the examination of whether the tract-specific differences in
schizophrenia could be explained by the heterochronicity of normal cerebral WM
development. This analysis revealed that the age at which schizophrenia patients began to
demonstrate lower FA values, presumed due to accelerated aging, was robustly explained by
age at which normal peak myelination is achieved and by rate of normative age-related
decline (r= −0.61 and −0.80, respectively). The negative sign of the correlation coefficients
indicated that WM tracts that reach peak myelination later in life and those that have steeper
normal age-related decline suffered from earlier onset of schizophrenia-specific accelerated
aging. The same analysis when performed for the MDD cohort yielded no such
relationships. This provides the first evidence not only for relatively disease-specific
accelerated aging of cerebral WM in SCZ, but also suggests that tracts that follow a
prolonged path to maturity are more vulnerable to and show the earliest effect of SCZ-
related acceleration in aging.
Overall, our findings of accelerated decline in FA in SCZ were consistent with findings of
accelerated aging for several other biological measures previously reported in this
disorder(19, 20). A report by Friedman and colleagues demonstrated no significant FA
deficits in the young (age=20–25) first episode schizophrenia patients(20). Similar finding
were observed in our study: average FA=0.60±0.02 and 0.59 ±0.02 for patients and controls,
respectively, two-tailed t-test p=0.4, in this age range. The age at which schizophrenia
subjects began to demonstrate lower average FA values in our group (32.4±11.9) was
similar to that reported by Mori and colleagues (27 years)(19).
The rate of accelerated age-related decline (ratio of the βage coefficients) observed by Mori
was also similar to the rate observed in our cohort (3.0 and 2.8, respectively). In contrast to
schizophrenia, we found no evidence for accelerated FA decline in MDD patients. This
finding may be explained by published literature which reported reduced FA values for
MDD patients are localized to specific regions (28–32, 34, 43).
The biological basis of the accelerated decline in FA values in schizophrenia may reflect
different neuropathological phenomena but accelerated decline in axonal myelination and/or
glial cell density is considered one of the likely causes (44–46). Accelerated decline in FA
values occurred primarily in the associative WM regions such as the genu of CC that have
long developmental trajectories. This protracted course may make it more vulnerable to
SCZ-related acceleration in aging. Postmortem studies in schizophrenia lend support to this
hypothesis by demonstrating a reduced expression of key oligodendrocyte/myelination
genes(47, 48) and reductions in the density of oligodendrocytes, specifically in the
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associative fiber tracts that connect prefrontal cortices(49, 50). In agreement, our data
demonstrated that the associative WM tracts showed a progressively younger age at which
schizophrenia patients began to differ from normal controls or having the “onset” of
accelerated aging. In fact, over 60% of regional variability in the tract-specific age of onset
was explained by the tract-wise normal rates of cerebral decline, making the normative
heterochronicity of FA maturation the single most important factor for the variable onset of
accelerated aging on white matter integrity across different fiber tracts in schizophrenia. The
protracted development of associative WM may render it to higher susceptibility to the
neurodegeneration associated with schizophrenia pathology or factors such as medication or
disease induced functional impairments.
Another plausible explanation for accelerated aging in cerebral WM is the genotype-by-age
interactions that affect cellular aging. For instance, genetic variation in TP53, a gene central
to DNA repair, oligodendrocyte senescence and apoptosis(51), is associated with deficits in
the white matter integrity and reduced neurochemicals such as N-acetylaspartate in the
frontal WM (51). The TP53 gene is also a candidate gene for schizophrenia(52, 53). Future
studies may explore whether this and other genetic variances may play a role in the WM
accelerated aging in schizophrenia.
This report is the first attempt to carefully evaluate evidence for accelerated aging in two
common psychiatric disorders. We attempted to minimize the impact of common age-related
metabolic disorders such as hypertension, diabetes, heart disorders and stokes by excluding
affected subjects from both cohorts. We cannot rule out effects from chronic antipsychotic
exposure in SCZ cohort. The correlation between whole-brain FA and current antipsychotic
medication dose, as calculated by chlorpromazine equivalent (CPZ), was not significant
(r=0.02; p=0.9). Similar findings were observed for correlation between CPZ and regional,
by tract, FA measurements (all r<=0.15, all p>0.25). This design would not allow
differentiation or even speculation if the findings in SCZ cohort are primarily caused by the
schizophrenia etiology, or by the effects of chronic antipsychotic medication exposure.
Ascertainment of large antipsychotic-naive SZ patient group across different ages to rule out
medication effects is difficult but a recent study in newly diagnosed, antipsychotic-naive
men demonstrated lower testosterone level, which was thought to be consistent with
accelerated aging hypothesis(54).
Mental disorders are also associated with lower socioeconomic status and exposure to
chronic stress, both of which are considered unfavorable mediators of aging(2). These
factors could increase the likelihood of physical disease and lead to accelerated aging in
SCZ. However, these factors can be the predisposition and/or the consequences of SCZ,
making a confirmatory analysis difficult. Nevertheless, lower socioeconomic status and
chronic stress are commonly reported in both mental disorders, and yet we did not observe
WM accelerated aging in the MDD patients. Recent research identified several cellular
biomarkers that may potentially be sensitive to chronic stress exposure (55, 56). Further
studies will be necessary to evaluate if these biomarkers can predict the WM aging trends in
SCZ.
There was a higher incidence of smoking in SCZ (Table 1). Short-term tobacco smoking is
associated with elevation in FA (57, 58), while long-term smoking leads to decline in FA
(59, 60). We re-analyzed our data only in non-smoker SCZ vs. non-smoker controls, and
found that SCZ patients still experienced higher rates of age-related decline than normal
controls (βage*scz = −0.0015±0.0006, t=1.8; p=0.06). While this is not significant due to
small sample, there is a clear trend that is consistent with the finding of accelerated aging of
white matter integrity in SCZ.
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Many studies have identified abnormal FA in SCZ and MDD, to the point that they appear
all the same. The difference on the age-related decline trend in FA between the two illnesses
provides an important insight on the nature of the illness-specific FA changes. Note that our
conclusions regarding the diagnostic specificity of accelerated aging are limited by the use
of the two cohorts with different backgrounds and somewhat different imaging parameters.
However, each disease cohort has own matched controls of the same population
background, and we applied the same data analysis approach for both cohorts. These
approaches provided assurance that the identified disease-specific accelerated aging cannot
be biased by differences in the controls.
This study is limited by the smaller size of the schizophrenia cohort. Nonetheless, the
finding was statistically significant and this finding’s biological validity was further
supported by a strong association with WM heterochronicity, a well-established biological
process. This study is also limited by the cross-sectional nature of the data, which could
biases the finding due to heterogeneity of individual aging trends. Additionally, a shorter life
span of schizophrenia patients compared with the controls may bias the estimate of the
accelerated aging, although this bias would likely lead to less differences found. Overall, the
aim of the study was to examine whether accelerated aging is present in one or both of the
key psychiatric illnesses, for which we found relatively clear evidence of disease-specific
accelerated aging in schizophrenia but not in major depressive disorder.
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Average DTI FA values were measured for twelve major cerebral WM tracts. Genu of
Corpus Callosum (GCC), Body of Corpus Callosum (BCC), Splenium of Corpus Callosum
(SCC), Cingulum (CG), Corona Radiata (CR), External Capsule (EC), Internal Capsule (IC),
Superior Frontal-Occipital (SFO), Inferior Frontal Occipital (IFO), Thalamic Radiation
(TR), Sagittal Stratum (SS), Superior Longitudinal Fasciculus (SLF).
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Whole brain average FA values in schizophrenia patients (top) and major depressive
disorder patients (bottom) compared with normal controls. The plots on the left are from the
raw FA values. The aging trends were regressed using a polynomial model (Eq. 2) from the
raw FA values. The plots on the right are the residual values that were z-normalized so that
the regression line across age (x-axis) was horizontal for the normal controls, for easy
visualization. Notable is that the slopes of the decline in FA values with age was significant
in schizophrenia (y = −0.031× + 0.96; r = 0.32, p=0.02) but not in the MDD (y = −0.0008×
+ 0.021; r = 0.00; p=0.99) patients.
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Whole brain average FA values (z-normalized to normal controls) in single episode and
recurrent MDD patients were similar.
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Age of X-intercept for schizophrenia patients plotted for twelve WM tracts is correlated with
normative variations in tract-specific rate of age-related decline (y=−0.75*x+60.9; r=−0.81)
(top graph) and age of FA peak (y=−0.48*x+48.5; r=−0.60) (bottom graph). †Normative
data is taken from(27), also tabulated in Table 1. Genu of Corpus Callosum (GCC), Body of
Corpus Callosum (BCC), Splenium of Corpus Callosum (SCC), Cingulum (CG), Corona
Radiata (CR), External Capsule (EC), Internal Capsule (IC), Superior Frontal-Occipital
(SFO), Inferior Frontal Occipital (IFO), Thalamic Radiation (TR), Sagittal Stratum (SS),
Superior Longitudinal Fasciculus (SLF)
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